A frequentist random-effects network meta-analysis pooling 9 RCTs (N = 5,766; durations 20–72 weeks) compared four oral GLP-1 receptor agonists — semaglutide, orforglipron, danuglipron, and lotiglipron — against placebo in adults with overweight or obesity but no diabetes. High-dose oral semaglutide reduced body weight by 11.6% and BMI by 4.7 kg/m², while high-dose orforglipron achieved the greatest absolute loss at 12.2 kg and a comparable 11.8% reduction. Low-dose lotiglipron was the sole agent failing to outperform placebo. Evidence certainty was rated low to moderate throughout.
The practical significance here is substantial. Injectable semaglutide (Wegovy) already commands the obesity pharmacotherapy landscape, but adherence barriers — cost, needle aversion, cold-chain logistics — limit real-world reach. A pill delivering equivalent magnitude effects could dramatically expand access. Orforglipron's emergence is particularly noteworthy: as a non-peptide small molecule, it requires no refrigeration and may carry manufacturing cost advantages over peptide-based agents like semaglutide.
Critical caveats temper enthusiasm. No head-to-head trials between these oral agents exist yet, making rankings network-derived estimates with inherent uncertainty. Trial durations maxed at 72 weeks — insufficient to assess cardiovascular outcomes or weight regain trajectories. The non-diabetic restriction means cardiometabolic benefit data remain extrapolated from diabetes trials. Overall, this is confirmatory and directionally important, but phase 3 head-to-head data will be essential before clinical preference hierarchies solidify.